🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Kite, A Gilead Company clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA and UK registers with Kite, A Gilead Company as lead sponsor. Synced 26 Sep 2026
11Current trials
3Recruiting now
19Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Kite, A Gilead Company is the lead sponsor of 11 current clinical trials in our USA and UK registers. 3 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Cyclophosphamide, Fludarabine and Axicabtagene Ciloleucel. The most-studied condition is Multiple Myeloma.

ClinicalTrials.gov trials by status

  • Recruiting327%
  • Active, closed655%
  • By invitation218%

Trials by phase

  • Phase 3436%
  • Phase 1436%
  • Phase 1/219%
  • Observational19%
  • Phase 219%
01

Clinical trials sponsored by Kite, A Gilead Company

11 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
NCT07479797 · Relapsed or Refractory Large B-cell Lymphoma
Phase 3 Recruiting 2026-05 UK, USA
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
NCT04989803 · ClinicalTrials.gov ↗ · Relapsed and/or Refractory B-cell Lymphoma
Phase 1/2 Recruiting 2021-10 UK, USA
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT07304154 · ClinicalTrials.gov ↗ · Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
Phase 1 Recruiting 2026-04 USA
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
NCT07038447 · Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
Phase 1 By invitation 2025-07 USA
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
NCT05041309 · ClinicalTrials.gov ↗ · Solid and Hematological Malignancies, Autoimmune Diseases
Observational By invitation 2021-12 UK, USA
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498 · Multiple Myeloma
Phase 3 Active, closed 2024-08 UK, USA
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05371093 · Relapsed/Refractory Follicular Lymphoma
Phase 3 Active, closed 2022-09 UK, USA
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
NCT04155749 · Relapsed and Refractory Multiple Myeloma
Phase 1 Active, closed 2019-12 USA
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899 · ClinicalTrials.gov ↗ · High-risk Large B-cell Lymphoma (LBCL)
Phase 3 Active, closed 2023-02 UK, USA
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
NCT06079164 · ClinicalTrials.gov ↗ · Relapsed/Refractory Large B-cell Lymphoma
Phase 1 Active, closed 2023-11 USA
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885 · ClinicalTrials.gov ↗ · Multiple Myeloma
Phase 2 Active, closed 2022-07 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Kite, A Gilead Company trials

19 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Kite, A Gilead Company trials

16 conditions
Multiple Myeloma2Relapsed or Refractory Large B-cell Lymphoma1Relapsed/Refractory Follicular Lymphoma1High-risk Large B-cell Lymphoma (LBCL)1Relapsed and/or Refractory B-cell Lymphoma1Solid and Hematological Malignancies1Autoimmune Diseases1Systemic Lupus Erythematosus1Lupus Nephritis1Systemic Sclerosis1Idiopathic Inflammatory Myopathy1Relapsed and Refractory Multiple Myeloma1Relapsed/Refractory Large B-cell Lymphoma1Chronic Inflammatory Demyelinating Polyneuropathy1Myasthenia Gravis1Multiple Sclerosis1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA113
Clinical trials in UK62

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Multiple Myeloma

SponsorTrials
Janssen Research & Development24
AbbVie13
GlaxoSmithKline13
Pfizer8
Celgene5
Zhujiang Hospital4
Regeneron Pharmaceuticals3
European Myeloma Network3
Nanjing IASO Biotechnology3
Genrix (Shanghai) Biopharmaceutical3

Sponsors with the most current trials registered for this condition.

06

Questions about Kite, A Gilead Company trials

How many clinical trials does Kite, A Gilead Company sponsor?

Kite, A Gilead Company is the lead sponsor of 11 current trials on ClinicalTrials.gov in our USA and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Kite, A Gilead Company trials recruiting?

Yes. 3 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Kite, A Gilead Company testing?

Its current trials name 19 drugs and biologicals as interventions. The most frequent are Cyclophosphamide (8), Fludarabine (8), Axicabtagene Ciloleucel (4), KITE-363 (4) and Anitocabtagene-autoleucel (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.